| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/29/2002 | EP1207887A2 Use of hepoxilins or hepoxilin analogs as antidiabetic, antiinflammatory agents |
| 05/29/2002 | EP1207886A2 Sphingomyelinase inhibitor |
| 05/29/2002 | EP1207885A1 Dietary supplement energy-providing to skeletal muscles and protecting the cardiovascular tract |
| 05/29/2002 | EP1207884A2 Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes |
| 05/29/2002 | EP1207883A1 Use of at least one substance based on nicotine and/or a substance produced from said one substance for the manufacture of a medicament, and a method for treatment of obstructive lung diseases |
| 05/29/2002 | EP1207882A1 Acyclic and cyclic amine derivatives |
| 05/29/2002 | EP1207881A1 Pharmaceutical agent comprising a benzamide derivative as active ingredient |
| 05/29/2002 | EP1207880A1 Torsemide polymorphs |
| 05/29/2002 | EP1207879A1 Nicotine receptor agonists in stem cell and progenitor cell recruitment |
| 05/29/2002 | EP1207878A2 Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof |
| 05/29/2002 | EP1207877A1 Anti-inflammatory actions of cytochrome p450 epoxygenase-derived eicosanoids |
| 05/29/2002 | EP1207876A1 Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor |
| 05/29/2002 | EP1207875A1 Pharmaceutically stable oxaliplatinum preparation for parenteral administration |
| 05/29/2002 | EP1207874A1 Methods of treating proliferative disorders |
| 05/29/2002 | EP1207873A1 Methods of inhibiting osteoclast activity |
| 05/29/2002 | EP1207872A1 Ibuprofen-containing softgels |
| 05/29/2002 | EP1207871A2 Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections |
| 05/29/2002 | EP1207870A1 Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field |
| 05/29/2002 | EP1207869A2 Antimycotic drug |
| 05/29/2002 | EP1207868A1 Pharmaceutical tramadol salts |
| 05/29/2002 | EP1207867A1 Oral pharmaceutical forms of administration with a delayed action |
| 05/29/2002 | EP1207866A1 Delayed-action form of administration containing tramadol saccharinate |
| 05/29/2002 | EP1207865A1 Composition for treatment of infections of humans and animals |
| 05/29/2002 | EP1207864A2 Compositions useful as inhibitors of erk |
| 05/29/2002 | EP1207863A2 New uses for potassium channel openers, such as the treatment of epilepsy |
| 05/29/2002 | EP1207862A2 Arthritis treatment |
| 05/29/2002 | EP1207861A1 Treatment of fungal infections utilizing a fungal growth medium |
| 05/29/2002 | EP1207859A1 Oral form of administration containing probiotic micro-organisms |
| 05/29/2002 | EP1207858A1 Oral dosage forms |
| 05/29/2002 | EP1207857A1 Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof |
| 05/29/2002 | EP1207856A2 Coformulation methods and their products |
| 05/29/2002 | EP1207855A1 Pharmaceutical composition comprising nabumetone |
| 05/29/2002 | EP1207852A1 Controlled release oral dosage suitable for oral administration |
| 05/29/2002 | EP1207851A1 Topical organic ectoparasiticidal formulations |
| 05/29/2002 | EP1207840A1 Pharmaceutical compositions and methods for reducing the appearance of cellulite |
| 05/29/2002 | EP1207811A1 Nitric oxide releasing medical devices |
| 05/29/2002 | EP1207809A1 Metering and packaging of controlled release medication |
| 05/29/2002 | EP1207757A1 Ectoparasiticidal aqueous suspension formulations of spinosyns |
| 05/29/2002 | EP1207756A1 Oral treatment of companion animals with ectoparasiticidal spinosyns |
| 05/29/2002 | EP1104419B1 N-substituted azabicycloheptane derivatives, production and use thereof |
| 05/29/2002 | EP1061812A4 Food products having enhanced cocoa polyphenol content and processes for producing same |
| 05/29/2002 | EP1023071A4 Method for inhibiting development of liver cancer and increasing survival in chronic hepadnavirus infection |
| 05/29/2002 | EP0991637B1 Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors |
| 05/29/2002 | EP0981646A4 Enzymatic dna molecules |
| 05/29/2002 | EP0923382B1 Compositions of plant carbohydrates as dietary supplements |
| 05/29/2002 | EP0915696B1 ANTI-beta-AMYLOID PROTEIN-INDUCED CYTOTOXICITY COMPOSITION |
| 05/29/2002 | EP0888325B1 Novel cyclic amino acids as pharmaceutical agents |
| 05/29/2002 | EP0880496B1 Biphenyl compounds and use thereof as oestrogenic agents |
| 05/29/2002 | EP0857066B1 Use of nitroflavonoids for the treatment of anxiety |
| 05/29/2002 | EP0799023B1 Use of flavonoids as immunomodulating or immuno-protective agents in cosmetic and dermatological preparations |
| 05/29/2002 | EP0786457B1 Azole derivatives |
| 05/29/2002 | EP0774974B1 Nucleic acid vaccine |
| 05/29/2002 | EP0752002B1 Inhibition of arterial smooth muscle cell proliferation |
| 05/29/2002 | EP0678021B1 Methods for the improvement of cognition with partial agonists of the glycine nmda receptor complex |
| 05/29/2002 | DE10059053A1 Anticoagulant composition containing anticoagulant in acidic solution or suspension useful e.g. for treatment of thrombosis and for promotion of wound healing |
| 05/29/2002 | DE10059020A1 Parenteral applizierbare Darreichungsformen Dosage forms can be administered parenterally |
| 05/29/2002 | DE10058663A1 Verwendung von Thienopyrimidinen Use of Thienopyrimidinen |
| 05/29/2002 | DE10058662A1 Verwendung von Pyrazolo[4,3-d]pyrimidinen Use of pyrazolo [4,3-d] pyrimidines |
| 05/29/2002 | DE10057976A1 Verfahren zur Herstellung von Pektinhydrolyseprodukten A process for producing pectin hydrolysis products |
| 05/29/2002 | DE10056351A1 Pharmaceutical preparation containing omega-3 fatty acids and other active substances e.g. an antiinflammatory, cyclooxygenase II inhibitor, 5-lipoxygenase inhibitor or platelet aggregation inhibitor |
| 05/29/2002 | DE10028443C1 Production of optically active 3,3-diaryl-propylamine derivatives comprises six step process from 4-hydroxybenzoic acid or alkyl 4-hydroxybenzoate and cinnamic acid |
| 05/29/2002 | CN1351661A Compounds |
| 05/29/2002 | CN1351608A B-methyl-erythromycin derivatives |
| 05/29/2002 | CN1351607A Novel crystalline forms of macrolide antibiotic |
| 05/29/2002 | CN1351606A Halo derivatives of 9-Deoxo-9a-Aza-9a-Homery theromycin A |
| 05/29/2002 | CN1351604A Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 05/29/2002 | CN1351602A New pharmaceutically active compounds |
| 05/29/2002 | CN1351601A Heterocyclic compounds binding chemotactic factor receptor |
| 05/29/2002 | CN1351600A Process for preparing [S-(R*,S*)]-beta-[[[1-[1-OXO-3-(4-piperidinyl)propyl]-3-piperidinyl]amino]-3-pyridinepropanoic acid and derivatives |
| 05/29/2002 | CN1351599A Indole-type derivatives as inhibitors of P38 kinase |
| 05/29/2002 | CN1351598A Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions |
| 05/29/2002 | CN1351597A Novel polymorphic forms of an antidiabetic agent, for their preparation and pharmaceutical compositions containing them |
| 05/29/2002 | CN1351595A Substituted polycyclic aryl and heteroacryl pyrazinones useful for selective inhibition of the coagulation cascade |
| 05/29/2002 | CN1351594A Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
| 05/29/2002 | CN1351593A Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants agents |
| 05/29/2002 | CN1351592A Acyl derivatives which treat VL4-4 related disorders |
| 05/29/2002 | CN1351591A 抗炎吲哚衍生物 Indomethacin derivative |
| 05/29/2002 | CN1351590A Compounds |
| 05/29/2002 | CN1351589A Vitamin D analogues and their pharmaceutical use |
| 05/29/2002 | CN1351588A Inhibitors of LFA-l binding to ICAMs and uses thereof |
| 05/29/2002 | CN1351561A Method and apparatus for distributing powder |
| 05/29/2002 | CN1351504A Preventives/remedies for interstitial pneumonia and pulmonary fibrosis |
| 05/29/2002 | CN1351499A Composition pharmaceutique |
| 05/29/2002 | CN1351498A Pyrrolotriazines inhibitors of kinases |
| 05/29/2002 | CN1351497A Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| 05/29/2002 | CN1351496A Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
| 05/29/2002 | CN1351495A Liposome compositions for improved drugretention |
| 05/29/2002 | CN1351494A Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations |
| 05/29/2002 | CN1351492A synergistic effects of amlodipine and atorvastatin |
| 05/29/2002 | CN1351491A Salts of cis-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-carboxylate] |
| 05/29/2002 | CN1351490A Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases |
| 05/29/2002 | CN1351488A Drinkable pharmaceutical solution |
| 05/29/2002 | CN1351487A Methods for regulating the condition of mammalian keratinous tissue via topical application of phytosterol compositions |
| 05/29/2002 | CN1351468A (s)-Enantiomer enriched tipronil composition |
| 05/29/2002 | CN1350863A Medicine for treating onychomycosis |
| 05/29/2002 | CN1350857A Face-beautifying ointment and its preparing process |
| 05/29/2002 | CN1350850A Soft capsule of superfine compound pearl powder and its preparing process |
| 05/29/2002 | CN1350849A Application of oxymetrine in preparing medicine to treat liver fibrosis |
| 05/29/2002 | CN1350848A Application of oxymatrine in preparing medicine to treat viral hepatitis C |
| 05/29/2002 | CN1350847A Indications of Fusaimi |